Retro and prospective Evaluation of the results of biopsies and ablations of renal massens at the University Medical Center Goettinge

Recruiting

• Conditions: C64; Malignant neoplasm of kidney, except renal pelvis

• Registration Number: DRKS00028690
• Lead Sponsor: niversitätsmedizin Göttingen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-05-23
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Patients >/=18 years of age with renal tumor biopsy and/or ablation

Exclusion Criteria

Patients <18 years and such that are not able to understand the study or sign informed consent

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Primary endpoint for the biopsies is the diagnostic accuracy evaluated by the rate of diagnostic biopsies. Non-diagnostic biopsies are biopsies with too few, fibrotic material or biopsy cores outside the tumor lesion. For the ablation techniques we evaluate rates of local recurrence (therapeutic efficiency).

Secondary Outcome Measures

Name	Time	Method
For both interventions we will evaluate complication rates after Clavien-Dindo. For biopsies the further therapeutic measures will be documented (resection, ablation, surveillance). For the ablations rates of metastases, survival (overall and cancer specific) and long term complications will be documented.